SENTARA HEALTH PLANS

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-844-668-1550</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization can be delayed</u>.

<u>For Medicare Members:</u> Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx. Additional indications may be covered at the discretion of the health plan.

Drug Requested: Vibativ® (telavancin) (J3095) (Medical)

MEMBER & PRESCRIBER INFOR	AMATION: Authorization may be delayed if incomplete.			
Member Name:				
Member Sentara #:	Date of Birth:			
Prescriber Name:				
Prescriber Signature:	Date:			
Office Contact Name:				
Phone Number:	Fax Number:			
NPI #:				
DRUG INFORMATION: Authorization may be delayed if incomplete.				
Drug Form/Strength:				
Dosing Schedule:	Length of Therapy:			
Diagnosis:	ICD Code, if applicable:			
Weight (if applicable):	Date weight obtained:			
Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.				
	all that apply. All criteria must be met for approval. To including lab results, diagnostics, and/or chart notes, must be			
Length of Authorization: Date of Ser	vice (14 days)			
□ New Start				

(Continued on next page)

	Member is 18 years of age or older				
	Member has a diagnosis of complicated skin and skin structure infections (cSSSI)				
	Provider has submitted lab cultures from current hospital admission or office visit collected within the las 7 days				
	Lab cultures must show that bacteria is sensitive to Vibativ or vancomycin				
	Member must meet ONE of the following:				
	Provider must submit chart notes documenting trial and failure of <u>ALL</u> the following oral antibiotics: penicillin VK, amoxicillin, amoxicillin-clavulanate, dicloxacillin, cephalexin, clindamycin, doxycycline, trimethoprim-sulfamethoxazole, and linezolid				
	Cultures (retrieved from most recent office visit or current inpatient admission collected within the last 7 days) shows resistance to <u>ALL</u> the following oral antibiotics: penicillin VK, amoxicillin, amoxicillin-clavulanate, dicloxacillin, cephalexin, clindamycin, doxycycline, trimethoprim-sulfamethoxazole, and linezolid				
	Member must meet ONE of the following:				
	Provider must submit chart notes documenting trial and failure of <u>ALL</u> the following IV antibiotics: penicillin G, nafcillin, ampicillin, ampicillin-sulbactam, cefazolin, ceftriaxone, vancomycin, daptomycin, clindamycin, and linezolid				
	Cultures (retrieved from most recent office visit or current inpatient admission collected within the last 7 days) shows resistance to <u>ALL</u> the following IV antibiotics: penicillin G, nafcillin, ampicillin, ampicillin-sulbactam, cefazolin, ceftriaxone, vancomycin, daptomycin, clindamycin, and linezolid				
ength of Authorization: Date of Service					
Continuation of therapy following inpatient administration					
	Member is currently on Vibativ for more than 72 hours inpatient (progress notes must be submitted)				
	Provider has submitted lab culture sensitivity results retrieved during inpatient admission which shows esistance to <u>ALL</u> preferred antibiotics except for Vibativ (sensitive)				
(Continued on next page)					

Medication being provided by (check applicable box(es) below):			
	Location/site of drug administration:		
	NPI or DEA # of administering location:		
	<u>OR</u>		
	Specialty Pharmacy		

For urgent reviews: Practitioner should call Sentara Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

Use of samples to initiate therapy does not meet step edit/preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.